JP2005519024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519024A5 JP2005519024A5 JP2003526406A JP2003526406A JP2005519024A5 JP 2005519024 A5 JP2005519024 A5 JP 2005519024A5 JP 2003526406 A JP2003526406 A JP 2003526406A JP 2003526406 A JP2003526406 A JP 2003526406A JP 2005519024 A5 JP2005519024 A5 JP 2005519024A5
- Authority
- JP
- Japan
- Prior art keywords
- branched
- hydrogen
- ring
- alkyl
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 116
- 239000001257 hydrogen Substances 0.000 claims description 116
- 150000002431 hydrogen Chemical class 0.000 claims description 78
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 229910052736 halogen Inorganic materials 0.000 claims description 56
- 150000002367 halogens Chemical class 0.000 claims description 51
- -1 cyano, carboxy Chemical group 0.000 claims description 45
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 38
- 229920006395 saturated elastomer Polymers 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 6
- 125000001589 carboacyl group Chemical group 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 31
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 125000001153 fluoro group Chemical group F* 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- SNNMYKHACBYNPF-SFHVURJKSA-N (2s)-1-[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl-2-(pyrrolidin-1-ylmethyl)pyrrolidine Chemical compound N1([C@@H](CCC1)CN1CCCC1)S(=O)(=O)C1=CC([N+](=O)[O-])=CC=C1OC1=CC(Cl)=CC(Cl)=C1 SNNMYKHACBYNPF-SFHVURJKSA-N 0.000 claims 3
- CXMDVJPSBFHFAZ-UHFFFAOYSA-N 1-[2-(3,5-dibromophenoxy)-5-nitrophenyl]sulfonylpiperazine Chemical compound C1CNCCN1S(=O)(=O)C1=CC([N+](=O)[O-])=CC=C1OC1=CC(Br)=CC(Br)=C1 CXMDVJPSBFHFAZ-UHFFFAOYSA-N 0.000 claims 3
- MWURPJRFLFHBRA-UHFFFAOYSA-N 1-[2-(3,5-dichloro-2-fluorophenoxy)-5-nitrophenyl]sulfonylpiperazine Chemical compound C1CNCCN1S(=O)(=O)C1=CC([N+](=O)[O-])=CC=C1OC1=CC(Cl)=CC(Cl)=C1F MWURPJRFLFHBRA-UHFFFAOYSA-N 0.000 claims 3
- YOUXJSFJQJOEAR-UHFFFAOYSA-N 1-[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl-1,4-diazepane Chemical compound C1CCNCCN1S(=O)(=O)C1=CC([N+](=O)[O-])=CC=C1OC1=CC(Cl)=CC(Cl)=C1 YOUXJSFJQJOEAR-UHFFFAOYSA-N 0.000 claims 3
- PZXBCZDWOYKAFB-UHFFFAOYSA-N 1-[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl-3,5-dimethylpiperazine Chemical compound C1C(C)NC(C)CN1S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 PZXBCZDWOYKAFB-UHFFFAOYSA-N 0.000 claims 3
- LPTOUQBSQLGFOP-UHFFFAOYSA-N 1-[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl-3-pyrrolidin-1-ylpyrrolidine Chemical compound C1CC(N2CCCC2)CN1S(=O)(=O)C1=CC([N+](=O)[O-])=CC=C1OC1=CC(Cl)=CC(Cl)=C1 LPTOUQBSQLGFOP-UHFFFAOYSA-N 0.000 claims 3
- SWZVWZBDHFNTLD-UHFFFAOYSA-N 1-[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl-4-pyrrolidin-1-ylpiperidine Chemical compound C1CC(N2CCCC2)CCN1S(=O)(=O)C1=CC([N+](=O)[O-])=CC=C1OC1=CC(Cl)=CC(Cl)=C1 SWZVWZBDHFNTLD-UHFFFAOYSA-N 0.000 claims 3
- DJXLHVLRWFRMAX-UHFFFAOYSA-N 1-[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl-n,n-diethylpyrrolidin-3-amine Chemical compound C1C(N(CC)CC)CCN1S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 DJXLHVLRWFRMAX-UHFFFAOYSA-N 0.000 claims 3
- GKHAHZQMENAZHG-UHFFFAOYSA-N 1-[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonylpiperazine Chemical compound C1CNCCN1S(=O)(=O)C1=CC([N+](=O)[O-])=CC=C1OC1=CC(Cl)=CC(Cl)=C1 GKHAHZQMENAZHG-UHFFFAOYSA-N 0.000 claims 3
- UZEKJXMJLMPEHG-UHFFFAOYSA-N 1-[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonylpiperazine-2-carboxylic acid Chemical compound OC(=O)C1CNCCN1S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 UZEKJXMJLMPEHG-UHFFFAOYSA-N 0.000 claims 3
- UNTKZXYTPPOUHO-UHFFFAOYSA-N 1-[2-(3,5-dichlorophenyl)sulfanyl-5-nitrophenyl]sulfonyl-4-pyrrolidin-1-ylpiperidine Chemical compound C1CC(N2CCCC2)CCN1S(=O)(=O)C1=CC([N+](=O)[O-])=CC=C1SC1=CC(Cl)=CC(Cl)=C1 UNTKZXYTPPOUHO-UHFFFAOYSA-N 0.000 claims 3
- UGKSLSUMQNVYAW-UHFFFAOYSA-N 1-[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl-1,4-diazepane Chemical compound CC1=CC(C)=CC(OC=2C(=CC(=CC=2)[N+]([O-])=O)S(=O)(=O)N2CCNCCC2)=C1 UGKSLSUMQNVYAW-UHFFFAOYSA-N 0.000 claims 3
- POXBXXTZUWRVJJ-UHFFFAOYSA-N 1-[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl-4-ethylpiperazine Chemical group C1CN(CC)CCN1S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1OC1=CC(C)=CC(C)=C1 POXBXXTZUWRVJJ-UHFFFAOYSA-N 0.000 claims 3
- LCDFCOUDXRXGBN-UHFFFAOYSA-N 1-[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl-4-propan-2-ylpiperazine Chemical compound C1CN(C(C)C)CCN1S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1OC1=CC(C)=CC(C)=C1 LCDFCOUDXRXGBN-UHFFFAOYSA-N 0.000 claims 3
- FLIQFYMILMDSAW-UHFFFAOYSA-N 1-[5-chloro-2-(3,5-dimethylphenoxy)phenyl]sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CC(Cl)=CC=C1OC1=CC(C)=CC(C)=C1 FLIQFYMILMDSAW-UHFFFAOYSA-N 0.000 claims 3
- QAAQMEREUWOLCE-UHFFFAOYSA-N 1-[5-cyano-2-(3,5-dichlorophenoxy)phenyl]sulfonylpiperazine-2-carboxylic acid Chemical compound OC(=O)C1CNCCN1S(=O)(=O)C1=CC(C#N)=CC=C1OC1=CC(Cl)=CC(Cl)=C1 QAAQMEREUWOLCE-UHFFFAOYSA-N 0.000 claims 3
- WRKKDSRZODVOKL-UHFFFAOYSA-N 3-(1,4-diazepan-1-ylsulfonyl)-4-(3,5-dichlorophenoxy)benzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CCNCCC2)=C1 WRKKDSRZODVOKL-UHFFFAOYSA-N 0.000 claims 3
- SYVJNCBQBAPSCK-UHFFFAOYSA-N 3-(1,4-diazepan-1-ylsulfonyl)-4-(3,5-dichlorophenyl)sulfanylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(SC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CCNCCC2)=C1 SYVJNCBQBAPSCK-UHFFFAOYSA-N 0.000 claims 3
- OCNYKXUWFGVIJA-UHFFFAOYSA-N 3-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-ylsulfonyl)-4-(3,5-dichlorophenoxy)benzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CC3CCCN3CC2)=C1 OCNYKXUWFGVIJA-UHFFFAOYSA-N 0.000 claims 3
- YGJRGROVYIAAEF-KDOFPFPSSA-N 3-[[(4ar,7ar)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]sulfonyl]-4-(3,5-dichlorophenoxy)benzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2C[C@@H]3NCCC[C@@H]3C2)=C1 YGJRGROVYIAAEF-KDOFPFPSSA-N 0.000 claims 3
- JFVOTMZEFSIFQC-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-3-(3-pyrrolidin-1-ylpyrrolidin-1-yl)sulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CC(CC2)N2CCCC2)=C1 JFVOTMZEFSIFQC-UHFFFAOYSA-N 0.000 claims 3
- SVJZYRLXAFKAGE-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-3-(4-pyrrolidin-1-ylpiperidin-1-yl)sulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CCC(CC2)N2CCCC2)=C1 SVJZYRLXAFKAGE-UHFFFAOYSA-N 0.000 claims 3
- FCRPFAFVEWSZBJ-UHFFFAOYSA-N 4-(3,5-dichlorophenoxy)-3-piperazin-1-ylsulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CCNCC2)=C1 FCRPFAFVEWSZBJ-UHFFFAOYSA-N 0.000 claims 3
- QBWFIHQVXQNTKR-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfanyl-3-piperazin-1-ylsulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(SC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CCNCC2)=C1 QBWFIHQVXQNTKR-UHFFFAOYSA-N 0.000 claims 3
- FQQMTRHHBWAIOR-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)sulfinyl-3-piperazin-1-ylsulfonylbenzonitrile Chemical compound ClC1=CC(Cl)=CC(S(=O)C=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CCNCC2)=C1 FQQMTRHHBWAIOR-UHFFFAOYSA-N 0.000 claims 3
- GLOJZOGSKZSTGZ-UHFFFAOYSA-N 4-(3,5-dimethylphenoxy)-3-piperazin-1-ylsulfonylbenzonitrile Chemical compound CC1=CC(C)=CC(OC=2C(=CC(=CC=2)C#N)S(=O)(=O)N2CCNCC2)=C1 GLOJZOGSKZSTGZ-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000023328 Basedow disease Diseases 0.000 claims 3
- 208000015023 Graves' disease Diseases 0.000 claims 3
- 206010037391 Pulmonary granuloma Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 206010039083 rhinitis Diseases 0.000 claims 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- 230000004957 immunoregulator effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003944 tolyl group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 0 C*1C(C)(C)CC(C)(C)[C@@](C)C(C)(C)N(C)C(C)(C)CC2(C)CC1(*)C2 Chemical compound C*1C(C)(C)CC(C)(C)[C@@](C)C(C)(C)N(C)C(C)(C)CC2(C)CC1(*)C2 0.000 description 7
- 150000002825 nitriles Chemical class 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001272327A JP2003081937A (ja) | 2001-09-07 | 2001-09-07 | ベンゼンスルホンアミド誘導体 |
| PCT/EP2002/009873 WO2003022277A1 (en) | 2001-09-07 | 2002-09-04 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005519024A JP2005519024A (ja) | 2005-06-30 |
| JP2005519024A5 true JP2005519024A5 (enExample) | 2006-01-12 |
| JP4517047B2 JP4517047B2 (ja) | 2010-08-04 |
Family
ID=19097717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001272327A Pending JP2003081937A (ja) | 2001-09-07 | 2001-09-07 | ベンゼンスルホンアミド誘導体 |
| JP2003526406A Expired - Fee Related JP4517047B2 (ja) | 2001-09-07 | 2002-09-04 | スルホンアミド誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001272327A Pending JP2003081937A (ja) | 2001-09-07 | 2001-09-07 | ベンゼンスルホンアミド誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7700586B2 (enExample) |
| EP (2) | EP1461038B9 (enExample) |
| JP (2) | JP2003081937A (enExample) |
| AR (1) | AR037235A1 (enExample) |
| CA (1) | CA2459432C (enExample) |
| DE (2) | DE60221569T2 (enExample) |
| ES (2) | ES2354378T3 (enExample) |
| GT (1) | GT200200178A (enExample) |
| HN (1) | HN2002000247A (enExample) |
| MY (1) | MY133303A (enExample) |
| PE (1) | PE20030440A1 (enExample) |
| SV (1) | SV2004001225A (enExample) |
| TW (1) | TWI262187B (enExample) |
| WO (1) | WO2003022277A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| AU2012238285B2 (en) * | 2003-03-24 | 2015-07-02 | Axikin Pharmaceuticals, Inc. | Benzenesulfonamide derivatives |
| KR101109296B1 (ko) * | 2003-03-24 | 2012-02-08 | 액시킨 파마수티컬스 인코포레이티드 | 천식 및 다른 염증성 또는 면역성 이상들의 치료용ｃｃｒ３ 길항 활성을 갖는 2-페녹시- 및2-페닐설폰아마이드 유도체 |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| EP2402316A1 (en) | 2005-07-21 | 2012-01-04 | AstraZeneca AB (Publ) | Piperidine derivatives |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| BRPI0710512A2 (pt) | 2006-04-20 | 2012-06-05 | Hoffmann La Roche | moduladores derivados de diazepan de receptores de quimiocinas |
| US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| US7897776B2 (en) | 2007-04-23 | 2011-03-01 | Salutria Pharmaceuticals Llc | Sulfonamide containing compounds for treatment of inflammatory disorders |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| EA020460B1 (ru) * | 2009-01-12 | 2014-11-28 | Пфайзер Лимитед | Производные сульфонамида |
| TW201036941A (en) * | 2009-03-30 | 2010-10-16 | Sumitomo Chemical Co | Method for producing sulfonamide compound |
| EP2417123A2 (en) | 2009-04-06 | 2012-02-15 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| WO2010123959A2 (en) * | 2009-04-22 | 2010-10-28 | Axikin Pharmaceuticals, Inc. | 2,5-disubstituted arylsulfonamide ccr3 antagonists |
| PL2421829T3 (pl) * | 2009-04-22 | 2016-03-31 | Axikin Pharmaceuticals Inc | 2,5-dipodstawione arylosulfonamidy jako antagoniści CCR3 |
| HUE025647T2 (en) | 2009-04-22 | 2016-04-28 | Axikin Pharmaceuticals Inc | Arylsulfonamide CCR3 antagonists |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| CR20170071A (es) | 2009-06-29 | 2017-03-28 | Agios Pharmaceuticals Inc | Compuestos terapeuticos y composiciones |
| EP2448581B1 (en) * | 2009-06-29 | 2016-12-07 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| US8999995B2 (en) * | 2010-03-02 | 2015-04-07 | Axikin Pharmaceuticals, Inc. | Isotopically enriched arylsulfonamide CCR3 antagonists |
| US8741894B2 (en) | 2010-03-17 | 2014-06-03 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide CCR3 antagonists |
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| US9096558B2 (en) | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
| EP2627635A1 (en) * | 2010-10-11 | 2013-08-21 | Axikin Pharmaceuticals, Inc. | Salts of arylsulfonamide ccr3 antagonists |
| EP2651898B1 (en) | 2010-12-17 | 2015-12-09 | Agios Pharmaceuticals, Inc. | Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
| WO2012088314A1 (en) | 2010-12-21 | 2012-06-28 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| ME03074B (me) | 2011-05-03 | 2019-01-20 | Agios Pharmaceuticals Inc | Akтivatori piruvat kinaze za upotrebu u terapiji |
| WO2012151440A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| KR20150053906A (ko) | 2012-09-07 | 2015-05-19 | 액시킨 파마수티컬스 인코포레이티드 | 동위원소 농축 아릴설폰아미드 ccr3 길항제 |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| MA44392B1 (fr) | 2015-06-11 | 2023-10-31 | Agios Pharmaceuticals Inc | Procédés d'utilisation d'activateurs de la pyruvate kinase |
| US12221463B2 (en) | 2020-08-07 | 2025-02-11 | The Board Of Regents Of The University Of Oklahoma | Method of promoting wound healing by inhibiting CCR3 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2275354A (en) * | 1937-11-29 | 1942-03-03 | May & Baker Ltd | Preparation of new therapeutically useful heterocyclic compounds |
| GB1368948A (en) * | 1970-11-11 | 1974-10-02 | Manuf Prod Pharma | Pyridine derivatives |
| US4233409A (en) * | 1979-07-05 | 1980-11-11 | Monsanto Company | Polymeric blend |
| DE3751728T2 (de) | 1987-12-14 | 1996-10-31 | Dow Chemical Co | Abs-zusammensetzungen mit trimodalkautschukteilchenverteilungen |
| US5041498A (en) * | 1990-01-02 | 1991-08-20 | The Dow Chemical Company | Trimodal ABS compositions having good gloss and reduced gloss sensitivity |
| DE4404749A1 (de) * | 1994-02-15 | 1995-08-17 | Bayer Ag | ABS-Polymer-Zusammensetzungen mit gleichmäßiger matter Oberfläche |
| US6057322A (en) * | 1995-01-30 | 2000-05-02 | Hoechst Aktiengesellschaft | Basically-substituted benzoylguanidines, a process for preparing them, their use as a medicament or diagnostic agent, and a medicament containing them |
| DE19507749A1 (de) * | 1995-03-06 | 1996-09-12 | Bayer Ag | Thermoplastische Formmassen vom ABS-Typ |
| DE19518025A1 (de) * | 1995-05-17 | 1996-11-21 | Bayer Ag | Thermoplastische ABS-Formmassen |
| ES2233275T3 (es) * | 1995-12-08 | 2005-06-16 | Agouron Pharmaceuticals, Inc. | Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas. |
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6262113B1 (en) * | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| DE19649249A1 (de) * | 1996-11-28 | 1998-06-04 | Bayer Ag | Verbesserte thermoplastische Formmassen vom ABS-Typ |
| US6284923B1 (en) * | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| EP1076557A1 (en) | 1998-04-27 | 2001-02-21 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| AU2201500A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| AU5600100A (en) | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| AU5473800A (en) | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| EP1237849A1 (en) * | 1999-11-05 | 2002-09-11 | University College London | Activators of soluble guanylate cyclase |
| DE10008420A1 (de) | 2000-02-23 | 2001-08-30 | Bayer Ag | Polymerzusammensetzungen mit verbesserter Eigenschaftskonstanz |
| DE10008419A1 (de) | 2000-02-23 | 2001-08-30 | Bayer Ag | Polymerzusammensetzungen mit verbesserter Eigenschaftskonstanz |
| JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| DE10145773A1 (de) | 2001-09-17 | 2003-04-03 | Bayer Ag | ABS-Zusammensetzungen mit verbesserten Eigenschaftskombinationen |
| KR101109296B1 (ko) * | 2003-03-24 | 2012-02-08 | 액시킨 파마수티컬스 인코포레이티드 | 천식 및 다른 염증성 또는 면역성 이상들의 치료용ｃｃｒ３ 길항 활성을 갖는 2-페녹시- 및2-페닐설폰아마이드 유도체 |
-
2001
- 2001-09-07 JP JP2001272327A patent/JP2003081937A/ja active Pending
-
2002
- 2002-08-29 AR ARP020103259A patent/AR037235A1/es not_active Application Discontinuation
- 2002-09-04 JP JP2003526406A patent/JP4517047B2/ja not_active Expired - Fee Related
- 2002-09-04 WO PCT/EP2002/009873 patent/WO2003022277A1/en not_active Ceased
- 2002-09-04 DE DE60221569T patent/DE60221569T2/de not_active Expired - Lifetime
- 2002-09-04 DE DE60238149T patent/DE60238149D1/de not_active Expired - Lifetime
- 2002-09-04 EP EP02772265A patent/EP1461038B9/en not_active Expired - Lifetime
- 2002-09-04 ES ES07013793T patent/ES2354378T3/es not_active Expired - Lifetime
- 2002-09-04 ES ES02772265T patent/ES2294167T3/es not_active Expired - Lifetime
- 2002-09-04 CA CA002459432A patent/CA2459432C/en not_active Expired - Fee Related
- 2002-09-04 EP EP07013793A patent/EP1849469B1/en not_active Expired - Lifetime
- 2002-09-04 US US10/489,029 patent/US7700586B2/en not_active Expired - Fee Related
- 2002-09-05 TW TW091120389A patent/TWI262187B/zh not_active IP Right Cessation
- 2002-09-05 GT GT200200178A patent/GT200200178A/es unknown
- 2002-09-06 HN HN2002000247A patent/HN2002000247A/es unknown
- 2002-09-06 PE PE2002000882A patent/PE20030440A1/es not_active Application Discontinuation
- 2002-09-06 MY MYPI20023349A patent/MY133303A/en unknown
- 2002-09-06 SV SV2002001225A patent/SV2004001225A/es not_active Application Discontinuation
-
2010
- 2010-04-19 US US12/763,072 patent/US8242118B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519024A5 (enExample) | ||
| RU2005132616A (ru) | Производные 2-фенокси и 2-фенилсульфонамида с ссr3 антагонистической активностью для лечения астмы и других воспалительных или иммунологических заболеваний | |
| DE60221569T2 (de) | Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen | |
| JP2006523627A5 (enExample) | ||
| JP2005513123A5 (enExample) | ||
| JP2006501295A5 (enExample) | ||
| RU2004137104A (ru) | Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| JP2002520309A5 (enExample) | ||
| RU2003129502A (ru) | Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний | |
| JP2008509187A5 (enExample) | ||
| JP2006515339A5 (enExample) | ||
| RU2005113168A (ru) | Производные 2-пиридона в качестве ингибитора нейтрофильной эластазы | |
| JP2005519908A5 (enExample) | ||
| RU2003120798A (ru) | Новые производные n-(фенилсульфонил) глицина и их применение в терапии | |
| NZ585085A (en) | Method of treating arthritis using arylsulfonamide compounds | |
| JP2004504404A5 (enExample) | ||
| RU2007101239A (ru) | Антагонисты рецептора вазопрессина v-1а | |
| JP2007509057A5 (enExample) | ||
| HUP0401735A2 (hu) | CCR1 receptor antagonista hatású piperazinszármazékok és ezeket tartalmazó gyógyászati készítmények | |
| RU2008143232A (ru) | Новый класс ингибиторов гистондеацетилаз | |
| JPWO2023195529A5 (enExample) | ||
| JP2004504400A5 (enExample) | ||
| RU2003104794A (ru) | Производные 4-фенилпиридина в качестве антагонистов рецептора нейрокинина 1 | |
| JP2022116001A5 (enExample) |